Neurology

Roche signs Icagen in neuro drug discovery deal worth up to USD 274 Million Roche and Icagen have signed a licensing and collaboration deal regarding ion channel modulators for neurological disorders. Icagen receives up to USD 274 million in development and commercial milestones. The duo will work on small molecules using Icagen’s platform for ion channels, targeting a specific ion channel target expressed in neurons. The agreement includes Icagen of handling preclinical work up to lead optimization, after that, both partners will work to identify candidates to move into IND-enabling studies. Also, Roche will be responsible for any development and commercialization of ...